Publications by authors named "D J Martinel Lamas"
Article Synopsis
- Gaucher Disease (GD) is a genetic condition caused by a deficiency in the enzyme glucocerebrosidase, and Velaglucerase alfa is used to replace this enzyme through therapy.
- Novel nanoparticle systems made from Eudragit have been developed to enhance the delivery and effectiveness of Velaglucerase alfa, demonstrating high stability and efficient encapsulation.
- In laboratory studies, these nanoparticles showed improved interaction with important proteins, better enzyme release in acidic conditions, and increased internalization in GD cells, leading to enhanced enzyme activity without affecting cell viability.
Background: The development and fine-tuning of biotechnological processes for fish oil extraction constitute a very important focus to contribute to the development of a food industry based on fish consumption. This work lies in a comparative analysis of the oil extraction yield of Myliobatis goodei livers using free and immobilized enzymes.
Results: An immobilized biocatalyst was designed from the cell-free extract of a Bacillus sp.
The dissolution rate of the anti-HIV drug saquinavir base (SQV), a poorly water-soluble and extremely low absolute bioavailability drug, was improved through a eutectic mixture formation approach. A screening based on a liquid-assisted grinding technique was performed using a 1:1 molar ratio of the drug and the coformers sodium saccharinate, theobromine, nicotinic acid, nicotinamide, vanillin, vanillic acid, and piperine (PIP), followed by differential scanning calorimetry (DSC). Given that SQV-PIP was the only resulting eutectic system from the screening, both the binary phase and the Tammann diagrams were adapted to this system using DSC data of mixtures prepared from 0.
View Article and Find Full Text PDFDaytime variation affects the tolerance of cardiomyocytes to ischemia-reperfusion injury (IRI). This study aims to evaluate the impact of time-of-day reperfusion on clinical outcomes of remote ischemic conditioning (RIC) as an adjuvant to primary percutaneous coronary intervention(PPCI) in ST-elevation myocardial infarction(STEMI) patients. A post-hoc analysis of a prospective, single-center parallel 1:1 randomized trial (RIC-STEMI) was performed.
View Article and Find Full Text PDF